S
Syndax Pharmaceuticals, Inc. (SNDX)
NMS – Real vaqt narxi. Valyuta: USD
20.41
-0.97 (-4.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
20.41
-0.97 (-4.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Syndax Pharmaceuticals, Inc., tijorat bosqichidagi biotexnologiya kompaniyasi, saratonni davolash uchun terapiyalarni ishlab chiqadi. Uning asosiy mahsulot nomzodlari orasida Revuforj (revumenib), qaytalangan yoki refrakter R/R o'tkir leykemiyani davolash uchun menin inhibitore; va Niktimvo (axatilimab-csfr), surunkali graft-versus-host kasalligini davolash uchun koloniya stimulyatsiya qiluvchi omil-1 retseptor blokirovka qiluvchi antitel bor. Kompaniya, shuningdek, revumenibni mNPM1 mutatsiyasi bilan R/R o'tkir miyeloid leykemiyasi (OML) va mNPM1 OML yoki KMT2Ar o'tkir leykemiyada standart davolash vositalari bilan birgalikda, shuningdek, metastatik kolorektal saraton uchun; axatilimabni idiopatik o'pka fibrozini davolash uchun; va Entinostatni, 1-sinf HDAC inhibitoreni ishlab chiqmoqda. U Entinostatni litsenziyalash, ishlab chiqish va tijoratlashtirish bo'yicha Eddingpharm International Company Limited bilan kelishuvga ega. Syndax Pharmaceuticals, Inc. 2005 yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Michael Downes Ph.D. | Co-Founder |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Mr. Keith Alan Goldan CPA | CFO, Treasurer & Principal Accounting Officer |
| Mr. Kevin McManus | Chief People Officer |
| Mr. Luke J. Albrecht J.D. | Senior VP, General Counsel & Secretary |
| Mr. Michael A. Metzger M.B.A. | CEO & Director |
| Mr. Steven Closter | Chief Commercial Officer |
| Sharon Klahre | Vice President of Investor Relations & Communications |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | sndx-20260430.htm |
| 2026-04-30 | 8-K | sndx-20260430.htm |
| 2026-02-26 | S-8 | sndx-20260226.htm |
| 2026-01-12 | 8-K | sndx-20260112.htm |
| 2025-12-19 | 8-K | sndx-20251218.htm |
| 2025-11-03 | 8-K | sndx-20251103.htm |
| 2025-10-24 | 8-K | sndx-20251024.htm |
| 2025-08-04 | 8-K | sndx-20250804.htm |
| 2025-08-04 | 10-Q | sndx-20250630.htm |
| 2025-06-26 | 8-K | sndx-20250624.htm |